In order to implement the decision-making and deployment of the Party Central Committee and the State Council and effectively support the prevention and control of the new crown epidemic in the Hong Kong Special Administrative Region, led by the Ministry of Industry and Information Technology, the emergency production and deployment of Ling Pharmaceutical, donated epidemic prevention materials worth 13.65 million yuan (about HK$16.8 million) through the Zhong Nanshan Medical Foundation of Guangdong Province to support the prevention and control of the epidemic in Hong Kong, including 200,000 boxes of Lianhua Qingxiao capsules and Lianhua qing cough tablets, Lianhua respiratory health kits, Lianhua Qingfeng antibacterial and antiviral masks, etc.
Ling Pharmaceutical's anti-epidemic materials arrived in Hong Kong
This batch of anti-epidemic materials has arrived in Hong Kong a few days ago, as an agent of Yiling Pharmaceutical in Hong Kong, Huang Guanghui, general manager of Hong Kong Quanchang Co., Ltd., said that he hopes to join hands with all walks of life in Hong Kong to overcome the difficulties together.
Huang Guanghui, general manager of Hong Kong Quanchang Co., Ltd., a Hong Kong agent of Yiling Pharmaceutical, was interviewed by the media
As a representative product of the "three medicines and three parties" of chinese medicine in mainland China, Lianhua Qingyi Capsule was approved for listing in Hong Kong in June 2018 as a "proprietary Chinese medicine". The State Key Laboratory of Respiratory Diseases published the study "Lianhua Qingpeng has antiviral and anti-inflammatory effects on the new coronavirus" published in the international mainstream journal of pharmacology research, which confirms that Lianhua Qingpeng plays an anti-new coronavirus activity by inhibiting viral replication and inhibiting the expression of host cell inflammatory factors. The latest research also found that whether it is alpha, Beta, or Delta and other mutant strains, even The Flower Qing Plague has shown a stable antiviral effect in vitro.
Lianhua Respiratory Health series products draw the essence of lianhua qing plague main drugs, with the same Chinese medicine anti-inflammatory and anti-viral genes. As a patented Traditional Chinese medicine approved during the new crown pneumonia in May 2020, Lianhua Cough Tablets has the effect of venting heat from the lungs, dissolving phlegm and relieving cough, and has multiple advantages for coughs caused by colds, influenza and new crown; and Lianhua respiratory health protection products are developed with the concept of "prevention before illness", which can effectively block the three transmission paths of germs "human-to-human", "matter-to-person" and "environmental-to-human", providing all-round health protection for the public.
It is understood that Lianhua Qingpeng has been approved for listing in nearly 30 countries and regions such as Russia, Canada, Brazil, Indonesia, Kuwait, Cambodia, etc., and has entered the white list of anti-epidemic drugs in many countries and the home treatment plan for mild patients.
[Reporter] Ou Xujiang
【Author】 Ou Xujiang
Healthy living circle